http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103509085-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-11 |
| filingDate | 2012-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103509085-B |
| titleOfInvention | The conjugate of androstane and RGD, its synthesis, anti-osteoporosis activity and application |
| abstract | The present invention relates to the conjugate of succinyl, 17 beta-amino-11 Alpha-hydroxy androstane-Isosorbide-5-Nitrae-diene-3-ketone and RGD and synthetic method thereof and application.The compounds of this invention is as shown in general formula I.AA is selected from Ser residue, Phe residue or Val residue.Mouse osteoporosis model evaluation that the present invention adopts prednisone the to induce anti-osteoporosis activity of the compounds of this invention.Test-results shows, the compounds of this invention has excellent anti-osteoporosis activity, can be prepared into osteoporosis agent.Under scanning electron microscope, the compounds of this invention has stable nanostructure. |
| priorityDate | 2012-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.